Contents:

CORONARY STENTS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Market Definitions and Scope of Study I-3 Bare Metal Stents I-3 Drug Eluting Stents I-3 II. Executive Summary 1. Global Market Overview II-1 Drug Eluting Stents Steal the Show II-1 Cypher and Taxus Dominate Global DES Market II-1 A 10-Year Outlook for the Coronary Stents Industry II-2 Current and Future Analysis II-3 2. Market Trends and Issues II-4 Drug Eluting Stent System - Safety Concerns II-4 Drug Eluting Stent Market to Bounce Back II-4 Coronary Stents Market Challenged by Drug Therapy II-4 Restenosis - the Real Growth Driver II-4 Table 1: Growth in Angioplasty Procedures Vs Stent Penetration Worldwide: (1997-2006) (includes corresponding Graph/Chart) II-5 Small Vessels - A Major Cause of Restenosis II-5 Aging Population Propels Coronary Stent Market II-5 Cell Transplantation - A Major Threat to Coronary Stents II-5 Next Generation Stents - A Boon for Treating Coronary Diseases II-6 Direct Stenting Systems Spur Growth II-6 Drug Choice Impacts Market Entry II-6 Price and Quality Concerns Dog Supplies and Demand for DES II-7 DES’ Introduction Skyrockets Coronary Stent Prices II-7 Legal Challenges Right Behind II-7 New Competition Puts Tabs on Coronary Stenting II-7 3. Competitive Analysis II-8 Coronary Stents - Leading Players II-8 Table 2: Leading Players in the Global Coronary Stents Market (2006-2008) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, Medtronic, and Others (includes corresponding Graph/Chart) II-8 Bare Metal Stents - Leading Players II-8 Table 3: Leading Players in the Global Bare Metal Stents Market (2006-2008) - Percentage Breakdown by Revenues for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) II-9 Drug-Eluting Stents - Leading Players II-9 Table 4: Leading Players in the Global Drug-Eluting Stent Market (2006-2008) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, and Medtronic (includes corresponding Graph/Chart) II-9 The Big Fight Heats Up in the Coronary Stent Market - A Recent Past (2005) Anecdote II-10 4. Product Overview II-12 Coronary Disease - A Perspective II-12 Factors Responsible for Coronary Diseases II-12 Controllable Risk Factors II-12 High Blood Cholesterol II-12 Sedentary Life Style and Habits II-12 Smoking Habits II-12 High Blood Pressure II-13 Uncontrollable Risk Factors II-13 Age II-13 Heredity II-13 Gender II-13 Causative Risk Factors II-13 Stress and Anger II-13 Obesity II-14 Symptoms of Coronary Artery Disease II-14 Diagnosis II-14 Treatment II-14 Drug Supported Treatments II-14 Invasive Treatments II-15 Bypass Surgery II-15 Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty) II-15 Natural Therapy II-15 Advancements in Coronary Disease Treatment Modalities II-16 University of Virginia’s Microbe Solution for Post Surgical Complications II-16 Radiation for Re-clogged Arteries Show Promise II-16 Radioactive Coronary Stents Promise Bright Future II-16 Coronary Stents II-16 Introduction II-16 Evolution of Coronary Stents II-17 Applications of Coronary Stents II-17 Stent Deployment II-18 Key Stent Delivery Platforms by Select Company II-18 Coronary Stent Designs II-19 Key Factors Determining Coronary Stent Performance II-19 Delivery Convenience II-19 Efficient Scaffolding II-19 Radiopacity (Visibility) II-19 Optimum Flexibility II-19 Shape Conformability II-19 Material for Coronary Stent II-20 Risk Associated with Stenting II-20 Improper Stent Implantation Likely Cause for In-Stent Restenosis II-20 Precautions II-21 What’s New in Coronary Stent Market? II-21 Direct Coronary Stenting - Creating an Enliven . II-22 Limitations II-22 Regulatory Approvals Wooing Stent Market II-23 A Peek into Regulatory Agency Approvals for Coronary Stents II-23 5. Product Segments II-26 Bare Metal Stents II-26 Major Bare Metal Stents by Company II-26 Drug-Eluting Stents II-26 DE Stents Overshadow Intravascular Brachytherapy Interventions II-27 Major Drug-Eluting Stents by Company II-27 Drugs for Coating DESs II-27 Cytotoxic or Cytostatic Drug - the Debate Continues II-28 Dosing and Deliverability Crucial for DES II-28 Polymer Coatings for Effective Dosing and Deliverability II-28 Drugs Used for DES by Major Competitors in the Stent Market II-28 Leading Coronary Stent Brands II-29 Cypher II-29 Structure and Delivery Mechanism II-29 Taxus II-29 Structure and Delivery Mechanism II-30 Multi-Link Vision II-30 BiodivYsio Added Support II-30 Eptifibatide ESPRIT II-30 6. Research and Development II-31 Extensive R&D Underway in Global Drug-Eluting Stents Market II-31 At the Labs II-31 Other Products Under Trials - A Recent Past Perspective II-31 OMT Developing R-stent II-31 Reva Developing Stainless Steel Bare-Metal Stent II-31 D & P Corp Developing Bovine Pericardium - Covered Stent II-31 Advanced Bio Synthesizing Porous Drug - Eluting Stents II-32 Lombard Medical Developing PEP Coatings II-32 Shiga Develops Biodegradable Drug-Eluting Stent II-32 7. Product Introductions II-33 InspireMD - MGuard™ Coronary Stent Launched in Italy II-33 CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin Polyzene®-F II-33 Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™ Stent in New Zealand II-33 Boston Scientific Launches Its Own Version of XIENCE™V Drug- Eluting Coronary Stent in Europe II-34 Guidant’s New Coronary Stent System Enters Japanese Realm II-34 Boston’s Gears Up for Market Expansion of TAXUS Liberte II-34 Trimax - A New Coronary Stent From Abbott II-35 JNJ Ramps Up Production of Cypher II-35 Occam Eyeing the International Markets II-35 Devax Offers Axxess Stent II-35 MIV Therapeutics Develops Metal Stent Coating Process II-35 8. Product Launches in the Recent Past II-36 Cordis Spearheads DES Revolution with the Rollout of Cypher II-36 New Duraflex Coronary Stent System From Avantec II-36 Abbott Launches Dexamet Drug-Eluting Stents in Europe II-36 Boston Scientific Introduces Drug-Eluting Stent in Europe II-36 Cordis Rolls Out Heparin Coated Coronary Stent II-36 Guidant Debuts Multi-Link Plus Intracoronary Stent in Japan II-36 Abbott Launches BiodivYsio Coronary Stent II-37 Guidant Rolls Out Tiny Artery Opening Stent Systems II-37 SMC Develops Plastic Stents for Coronary Artery II-37 JNJ Develops Drug Coated Coronary Stent II-37 Coronary Stent Introductions: A Historical Perspective II-37 9. Recent Industry Activity II-38 Medtronic Receives the US FDA Approval to Use Endeavor® Stent II-38 Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In Canada II-38 Boston Scientific to Market TAXUS® Liberte® Stent System in Canada II-38 Abbott Applies for Approval of XIENCE™ V in Japan II-38 Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent System II-39 Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary Stent II-39 Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark approval II-39 Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European Entry II-39 Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval II-39 CV Therapeutics Offers its Stent Coating Technology to Medlogics Device Corporation II-40 Abbott’s 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of Approval II-40 Biosensors Receives CE Mark Approval for BioMatrix® Stent System II-40 Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark Approval II-40 Cook Medical’s Zilver Stent Receives Approval for Vascular Use In Canada II-41 Boston Scientific to Market TAXUS® EXPRESS2 Stent System in Japan II-41 CE Mark Granted for the Use of Drug-eluting Stent, TAXUS® Liberte™ in Diabetic Patients II-41 Boston Scientific’s TAXUS® Liberte™ Long Stent Receives CE Mark Approval II-41 Boston Joins Forces with Guidant II-41 Avantec Licenses Blue Membranes’ Technology for DES II-42 FDA Nods for Usage of CYPHER® in Overlapping Stenting II-42 Guidant’s XIENCE™ V Gets CE Marked II-42 EuroCor Receives Definitive CE Mark Approval for Taxcor II-42 BIOTRONIK Ties Up with Novartis II-42 BIOTRONIK Collaborates with Micrus II-43 CYPHER Select™ PLUS Gets CE Nod II-43 Medtronic’s Micro-Driver Bags FDA Approval II-43 Conor Wins CE Mark Approval for CoStar™ II-43 Relisys Collaborates with Blue Membranes II-43 OCIL Steps Into the German Sphere by Acquiring EuroCor II-44 Boston Purchases Advanced Stent Technologies... II-44 Neich Medical Acquires Orbus Medical II-44 MIV Therapeutics To Purchase Assets of Sahajanand II-44 Conor’s Unistar Becomes CE Approved II-44 CE Clears DISA’s Small-Vessel Heart Stent II-44 Boston’s TAXUS Express2 for Larger Vessels Gets Lucrative Approvals II-44 Boston Inaugurates R&D Center II-45 Endovasc Forms Joint Venture with Tissuegen II-45 Avantec Vascular Signs Licensing Pact With Novartis II-45 Boston Acquires Rights from Angiotech II-45 Xtent and Occam International Enter Into Licensing Deal II-45 Angiotech and Cook Reorganize License Agreement II-46 CardioTech and Implant Sciences Join Forces II-46 Guidant and Cordis Sign Marketing Agreement II-46 CONOR and BIOTRONIK Ink Distribution Pact II-46 Boston Scientific Obtains FDA Approval for Taxus Stents II-46 ev3 Receives CE Mark Approval for Protege Stent II-47 DISA Gains CE Mark Approval II-47 10. Strategic Corporate Developments in the Past II-48 Guidant Acquires Biosensors’ Everolimus DES Assets II-48 Sun Biomedical Signs Sales and Licensing Agreement with Guidant II-48 Debiotech Receives License for DES Technology II-48 JNJ Wins FDA Approval for Cypher Stent II-48 Medtronic Obtains FDA Approval for Driver Coronary Stent II-48 Boston Receives CE Mark Approval II-49 Goodman Acquires Avantec II-49 Abbott Acquires Coronary Stent Business of Biocompatibles II-49 Guidant Expands Licensing Agreement with Novartis Pharma II-49 Abbott Signs Marketing Agreement with Medtronic II-49 Medtronic Sublicenses DES Coating Technology from Abbott II-49 Gore and Medinol Sign Collaborative Agreement II-49 Guidant Obtains CE Mark Approval II-50 Boston Scientific Receives Marketing Approval for Coronary Stent System II-50 Cook Obtains CE Approval for ACHIEVE™ Coronary Stent II-50 Snia Receives Clearance from TGA to Market Stents and Catheters II-50 OCIL Acquires Key Assets of AMDL II-50 Fujisawa and JOMED Join Forces II-51 British Biotech Enters into Collaboration with Biocompatibles II-51 AVI BioPharma and Medtronic Enter into Agreement II-51 Guidant Inks Distribution Agreement with Cook II-51 JNJ Wins FDA Approval for Bx Velocity Coronary Stent II-51 Cook Obtains Approval for Drug Coated Coronary Stent II-51 Medtronic Obtains FDA Approval for S660 Coronary Stent II-51 11. Clinical Trials and Key Studies II-53 Canadian Study Indicates Superior Clinical Benefits of Drug- Coated Stent II-53 SPIRIT III Trial Confirms Superiority of Everolimus Eluting Coronary Stent, XIENCE™ V Over TAXUS® Stent II-53 Network Meta-Analysis Demonstrates Low Mortality Rates for Both Drug-Eluting And Bare-Metal Stents II-53 Study Proves Superiority of Cypher® Sirolimus-Eluting Coronary Stent in Reduction of Blood Clot Risks and Reintervention Compared to Taxus Stent II-54 12. Focus on Select Players II-55 Angiotech Pharmaceuticals (Canada) II-55 Boston Scientific Corp. (USA) II-55 Cordis Corporation (JNJ) - (USA) II-56 Cook Group, Inc. (USA) II-56 Medtronic, Inc. (USA) II-56 Medtronic Cardiovascular, Inc. (USA) II-56 MIVI Technologies Inc. (Canada) II-57 OrbusNeich (USA) II-57 Sorin Biomedica Cardio (Italy) II-57 Sun Biomedical Ltd. (USA) II-57 13. Global Market Perspective II-58 Table 5: World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) II-58 Table 6: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2011 (includes corresponding Graph/Chart) II-59 Table 7: World Long-Term Projections for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-60 Table 8: World Long-Term Projections for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart) II-61 Table 9: World 10-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) II-62 Table 10: World 10-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart) II-63 Table 11: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) II-64 Table 12: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2011 (includes corresponding Graph/Chart) II-65 Table 13: World Long-Term Projections for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-66 Table 14: World Long-Term Projections for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart) II-67 Table 15: World 10-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) II-68 Table 16: World 10-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart) II-69 Table 17: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-70 Table 18: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2001 through 2011 (includes corresponding Graph/Chart) II-71 Table 19: World Long-Term Projections for Drug Eluting Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-72 Table 20: World Long-Term Projections for Drug Eluting Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2011 through 2016 (includes corresponding Graph/Chart) II-73 Table 21: World 10-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) II-74 Table 22: World 10-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2004, 2008 & 2013 (includes corresponding Graph/Chart) II-75 III. MARKET 1. United States III-1 A.Market Analysis III-1 Largest Market Worldwide III-1 Coronary Artery Disease - A US Perspective III-1 Rapid Adoption of DES Technology in the US Market III-1 Baby Boomers Boost Coronary Stent Market III-1 Key Drivers of the US DES Market III-2 Improved Treatment and Diagnosis III-2 Long-Term Cost Reduction III-2 Well-Organized Reimbursement System III-2 Growing Patient Awareness III-2 DES Technology - Economic Implications on the US Health Care System III-2 Soaring Costs of Multivessel Treatment - Still a Major Problem III-3 Competitive Scenario III-3 Leading Players III-3 Coronary Stents - Boston Scientific and JNJ Battle for Dominance III-3 Table 23: Leading Players in the US Coronary Stents Market (2006) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson and Others (includes corresponding Graph/Chart) III-3 Bare Metal Stents - Guidant Led all the Way III-4 Table 24: Leading Players in the US Bare Metal Stents Market (2006) - Percentage Breakdown by Revenues for Guidant (Abbott), Boston Scientific, Medtronic, Johnson & Johnson, Abbott Laboratories and Others (includes corresponding Graph/Chart) III-4 Drug Eluting Stents - Competition in the Brewing III-4 Table 25: Leading Players in the US Drug-Eluting Stents Market (2006, 2007 & 2008) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Medtronic and Abbott (includes corresponding Graph/Chart) III-4 Regulatory Environment III-5 Product Introductions III-5 Recent industry activity III-7 Review of Select Players III-14 Boston Scientific Corp. III-14 Cordis/JNJ III-15 Cook Group, Inc. III-15 Medtronic, Inc. III-15 Sun Biomedical Ltd III-16 B.Market Analytics III-16 Table 26: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-16 Table 27: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-17 Table 28: US Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-17 Table 29: US Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-18 Table 30: US 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-18 Table 31: US 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-18 2. Japan III-19 A.Market Analysis III-19 Prospects Weighed down by Regulatory Entanglements III-19 Japanese Government Steps in to Alleviate Pricing III-19 Japanese Coronary Stents Command Higher Prices III-19 Table 32: Coronary Stent Pricing (2005): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart) III-19 Competitive Landscape III-20 Table 33: Leading Players in the Japanese Coronary Stent Market (2004, 2005 & 2006) - Percentage Breakdown by Value Sales for Johnson & Johnson, Medtronic, Guidant, Boston Scientific, and Others (includes corresponding Graph/Chart) III-20 Table 34: Leading Players in the Japanese Bare Metal Stent Market (2004, 2005 & 2006) - Percentage Breakdown by Value Sales for Guidant, Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart) III-21 Table 35: Leading Players in Japanese Drug-Eluting Stent Market (2006, 2007 & 2008) - Percentage Breakdown by Revenues for Johnson & Johnson and Boston Scientific III-21 Product Introductions in the Recent Past III-22 Strategic Development III-22 Strategic Corporate Activity in the Recent Past III-23 B.Market Analytics III-23 Table 36: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-23 Table 37: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-24 Table 38: Japanese Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-24 Table 39: Japanese Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-25 Table 40: Japanese 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-25 Table 41: Japanese 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-25 3. Europe III-26 A.Market Analysis III-26 Cardiovascular Disease in Europe - A Perspective III-26 Table 42: European Cardiovascular Disease Treatment Procedures - A Historic View III-26 Growth Bar Too Low III-27 Table 43: Price of Stents in Europe & the United States for Years 2003-2006: A Comparison (includes corresponding Graph/Chart) III-27 Table 44: Average Annual Volume Growth of Coronary Stents in Europe Vs Global Average (2003-2008) III-27 Two-Speed Europe III-27 Dampeners to Rapid Adoption of DES in Europe III-28 Reimbursement Issues III-28 High Penetration Rates of Bare Metal Stents III-28 Skyrocketing Prices III-28 The Scenario Changes III-28 Stent Market’s Merger Mania III-28 Competitive Scenario III-28 Table 45: Leading Players in the European Bare Metal Stent Market (2004, 2005 & 2006) - Percentage Breakdown by Value Sales for Guidant, Medtronic, Boston Scientific, Johnson & Johnson, and Others (includes corresponding Graph/Chart) III-29 Table 46: Leading Players in the European Drug- Eluting Stent Market (2004, 2005 & 2006) - Percentage Breakdown by Value Sales for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) III-30 Product Introductions III-30 Recent Industry Activity III-32 B.Market Analytics III-37 Table 47: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-37 Table 48: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-38 Table 49: European Long-Term Projections for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-39 Table 50: European Long-Term Projections for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-40 Table 51: European 10-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) III-41 Table 52: European 10-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) III-42 Table 53: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2001 -2010 (includes corresponding Graph/Chart) III-43 Table 54: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2001 -2010 (includes corresponding Graph/Chart) III-43 Table 55: European Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-44 Table 56: European Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-44 Table 57: European 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-45 Table 58: European 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-45 3a. France III-46 Market Analysis III-46 Table 59: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-46 Table 60: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-47 Table 61: French Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-47 Table 62: French Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-48 Table 63: French 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-48 Table 64: French 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-48 3b. Germany III-49 Market Analysis III-49 Table 65: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-49 Table 66: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-50 Table 67: German Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-50 Table 68: German Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-51 Table 69: German 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-51 Table 70: German 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-51 3c. Italy III-52 A.Market Analysis III-52 Sorin Biomedica Cardio - A Key Player III-52 B.Market Analytics III-52 Table 71: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-52 Table 72: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-53 Table 73: Italian Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-53 Table 74: Italian Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-54 Table 75: Italian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-54 Table 76: Italian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-54 3d. United Kingdom III-55 Market Analysis III-55 Table 77: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-55 Table 78: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-56 Table 79: UK Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-56 Table 80: UK Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-57 Table 81: UK 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-57 Table 82: UK 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-57 3e. Spain III-58 Market Analysis III-58 Table 83: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-58 Table 84: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-59 Table 85: Spanish Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-59 Table 86: Spanish Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-60 Table 87: Spanish 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-60 Table 88: Spanish 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-60 3f. Russia III-61 Market Analysis III-61 Table 89: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-61 Table 90: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-62 Table 91: Russian Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-62 Table 92: Russian Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-63 Table 93: Russian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-63 Table 94: Russian 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-63 3g. Rest of Europe III-64 Market Analysis III-64 Table 95: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-64 Table 96: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-65 Table 97: Rest of Europe Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-65 Table 98: Rest of Europe Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-66 Table 99: Rest of Europe 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-66 Table 100: Rest of Europe 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-66 4. Asia-Pacific III-67 A.Market Analysis III-67 Coronary Stent Market in a Bubble Zone Now III-67 Regional Players and their DES Development Efforts III-67 Cost Focus Helps Stent Makers Win the Market Stunt III-67 Product Launch III-68 Recent Industry Activity III-68 B.Market Analytics III-69 Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-69 Table 102: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-69 Table 103: Asia-Pacific Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-70 Table 104: Asia-Pacific Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-70 Table 105: Asia-Pacific 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-71 Table 106: Asia-Pacific 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-71 5. Rest of World III-72 A.Market Analysis III-72 Market Leaders III-72 Table 107: Leading Players in the Rest of World Coronary Stent Market (2004, 2005 and 2006) - Percentage Breakdown by Value Sales for Johnson & Johnson, Guidant, Boston Scientific, Medtronic and Others (includes corresponding Graph/Chart) III-72 South Africa - Leading Players III-73 Table 108: Leading Players in South African Coronary Stent Market (2006) - Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott, Sorin, and Others (includes corresponding Graph/Chart) III-73 Recent Industry Activity III-73 Key Players III-73 B.Market Analytics III-75 Table 109: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2001 through 2010 (includes corresponding Graph/Chart) III-75 Table 110: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2001 through 2010 (includes corresponding Graph/Chart) III-75 Table 111: Rest of World Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2011 through 2015 (includes corresponding Graph/Chart) III-76 Table 112: Rest of World Long-Term Projections for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2011 through 2015 (includes corresponding Graph/Chart) III-76 Table 113: Rest of World 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-77 Table 114: Rest of World 10-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2004, 2008, and 2012 III-77 IV. COMPETITIVE LANDSCAPE

Companies Mentioned

The Companies Mentioned inside this Report include: Abbott Laboratories (USA) Angiotech Pharmaceuticals, Inc (Canada) Atrium Medical Corporation (USA) AVI Biopharma, Inc (USA) B Braun Melsungen AG (Germany) Biocompatibles UK Ltd (UK) Biotronik GmbH & Co (Germany) Biotronik, Inc (USA) Biotronik UK Ltd (UK) Blue Membranes GmbH (Germany) Bolton Medical, Inc (USA) Boston Scientific Corporation (USA) Guidant Corporation (USA) Guidant (Canada) Brittan Healthcare (Pty) Ltd (South Africa) CardioTech International, Inc (USA) ClearStream Technologies Limited (Ireland) Conor Medsystems, Inc (USA) Cook Group, Inc (USA) Debiotech SA (Switzerland) Devax, Inc (USA) Disa Vascular (Pty) Ltd (South Africa) Endologix, Inc (USA) Endovasc, Inc (USA) Eucatech AG (Germany) EuroCOR GmbH (Germany) EV, INC (USA) Goodman Co, Ltd (Japan) Avantec Vascular Corporation (USA) Hexacath (France) Implant Sciences Corporation (USA) Insitu Technologies, Inc (USA) Johnson & Johnson (USA) Cordis Corporation (USA) Cordis Europa NV (The Netherlands) Medinol Ltd (Israel) MediVas LLC (USA) Medtronic, Inc (USA) Medtronic Vascular Division (USA) MIV Therapeutics, Inc (Canada) Novartis Pharma Switzerland AG (Switzerland) Novoste Corporation (USA) Orbusneich (Hong Kong) Relisys Medical Devices (India) Sahajanand Medical Technologies (India) Shenzhen Lifetech Scientific, Inc (China) Shiga Medical Center (Japan) Snia SpA (Italy) Sorin Biomedica Cardio SpA (Italy) Sun Biomedical Ltd (USA) Biosensors International Pte, Ltd (Singapore) Occam International BV (The Netherlands) SurModics, Inc (USA) Terumo Corporation (Japan) TissueGen, Inc (USA) Vascular Concepts (India) W L Gore & Associates, Inc (USA) Carmeda AB (Sweden) X-Cell Medical, Inc (USA) Xtent, Inc (USA)